Of Timing and Surrogates: A Way Forward for Cancer Chemoprevention
Open Access
- 1 June 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (11) , 3509-3511
Abstract
Cancer chemoprevention strategies are not widely implemented in clinical practice. Targeting biomarkers in patients with elevated risk of developing cancer by means of short-term administration of certain agents may be a strategy to minimize toxicities while maintaining efficacy in clinical trials that can be completed in years rather than decades. Clin Cancer Res; 17(11); 3509–11. ©2011 AACR.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal PolypsClinical Cancer Research, 2011
- Cancer Chemoprevention—the Cardiovascular ModelCancer Prevention Research, 2011
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib TrialCancer Prevention Research, 2008
- Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and AspirinClinical Gastroenterology and Hepatology, 2006
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?Seminars in Oncology, 2005
- National Trends in Cyclooxygenase-2 Inhibitor Use Since Market ReleaseArchives of internal medicine (1960), 2005
- Potential Pitfalls in the Use of Surrogate Endpoints in Colorectal Adenoma ChemopreventionJNCI: Journal of the National Cancer Institute, 2003
- Prevention of Colorectal Cancer by Colonoscopic PolypectomyNew England Journal of Medicine, 1993